Comparable stake leader
Opaleye Management Inc.
SEC ownership of Grace Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001444192.
Disclosed value leader
Opaleye Management Inc.
Comparable rows
37/50
Latest evidence
28 Aug 2026
- Public ticker
- GRCE on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Opaleye Management Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
37 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Opaleye Management Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
28 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001444192
- Issuer location
- Princeton, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Grace Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Opaleye Management Inc.
Disclosed value leader
Opaleye Management Inc.
Comparable rows
37/50
Latest evidence
28 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 13%
13 rows are not safely comparable across share classes.
13D/G row: Opaleye Management Inc.
Showing 1-8 of 50 holder rows.
Quick read
Opaleye Management Inc. leads the comparable SEC ownership view at 13%.
37 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Opaleye Management Inc.'s linked filing trail.
Comparable ownership
Top 5
Opaleye Management Inc.
13%
ADAR1 Capital Management, LLC
9.9%
Nantahala Capital Management, LLC
6.8%
Orin Hirschman
4.9%
Cerity Partners LLC
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Opaleye Management Inc. |
13D/G
3/4/5
10%+ Owner
|
13%
|
$6,238,850
2,748,392 shares
|
$0 | 05 Aug 2026 |
| ADAR1 Capital Management, LLC |
13D/G
3/4/5
10%+ Owner
|
9.9%
|
$4,100,110
1,806,216 shares
|
+$201,553 | 30 Jun 2026 |
| Nantahala Capital Management, LLC |
13D/G
|
6.8%
|
$2,674,521
1,178,203 shares
|
-$927,195 | 30 Jun 2026 |
| Orin Hirschman |
13D/G
|
4.9%
|
—
814,000 shares
|
$0 | 31 Mar 2026 |
| Cerity Partners LLC |
13F
Company
|
4.7%
|
$1,927,355
849,055 shares
|
— | 30 Jun 2026 |
| Eversept Partners, LP |
13F
Company
|
4.2%
|
$1,754,483
772,900 shares
|
— | 30 Jun 2026 |
| BANK OF AMERICA CORP /DE/ |
13F
Company
|
2.7%
|
$1,122,964
494,698 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
2.3%
|
$934,591
411,714 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$24,206.
Buys
$24,206
Insiders: 1
Sells
$0
Insiders: 0
Net
+$24,206
Shares: +11,608
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 11,608
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 11,608 | 0 | $24,206 | $0 | +$24,206 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to Grace Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
Opaleye Management Inc.
Net 12M change
+$24,206
Latest report
28 Aug 2026
Recent insider transactions for Grace Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Amresh Kumar | GRCE | Stock Option (Right to Buy) | Award | 35,760 | 35,760 | 28 Aug 2026 | Direct | |||
| Prashant Kohli | GRCE | Stock Option (Right to Buy) | Award | 267,160 | 267,160 | 28 Aug 2026 | Direct | |||
| R. Loch Macdonald | GRCE | Stock Option (Right to Buy) | Award | 54,690 | 54,690 | 28 Aug 2026 | Direct | |||
| Robert J. DelAversano | GRCE | Stock Option (Right to Buy) | Award | 33,660 | 33,660 | 28 Aug 2026 | Direct | |||
| Opaleye Management Inc. | GRCE | Common Stock, par value $0.0001 per share | Purchase | 0.42% | $24,206 | $2.09 | 11,608 | 2,760,000 | 14 Aug 2026 | By Opaleye, L.P. |
| Vimal Kavuru | GRCE | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 08 Jan 2026 | Direct | |||
| George Kottayil | GRCE | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 08 Jan 2026 | Direct | |||
| Edward Neugeboren | GRCE | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 08 Jan 2026 | Direct | |||
| A. Brian Davis | GRCE | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 08 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.